Literature DB >> 10781383

Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease.

S J Cleland1, N Sattar, J R Petrie, N G Forouhi, H L Elliott, J M Connell.   

Abstract

Low-grade chronic inflammation, characterized by elevated plasma concentrations of C-reactive protein (CRP), is associated with an increased risk of atherosclerotic cardiovascular disease. Endothelial cell activation is an early event in atherogenesis, and previous studies have reported correlations between indirect markers of endothelial cell activation and CRP concentration. Therefore, in the present study, we measured CRP concentration (and leptin concentration as an index of fat mass) in nine healthy subjects (mean age 53+/-8.1 years; body mass index 27+/-3.2 kg/m(2); mean arterial blood pressure 101+/-9.0 mmHg) undergoing measurement of basal endothelial nitric oxide (NO) synthesis using intra-brachial infusions of N(G)-monomethyl-L-arginine (L-NMMA; a substrate inhibitor of endothelial NO synthase) and noradrenaline (a non-specific control vasoconstrictor). In univariate analysis, CRP concentration was correlated with (i) the percentage decrease in forearm blood flow (FBF) during L-NMMA infusion (r=0.85, P=0.004); and (ii) the serum leptin concentration (r=0.65, P=0.05). In multivariate analysis, the relationship between CRP concentration and the FBF response to L-NMMA remained significant when age and leptin (t=2.65, P=0.045), age and BMI (t=3.69, P=0.014), or age and low-density-lipoprotein-cholesterol plus high-density-lipoprotein-cholesterol (t=3.37, P=0.044), were included in regression models. In contrast, the response of FBF to noradrenaline was not significantly related to CRP concentration. These data demonstrate for the first time a relationship between low-grade chronic inflammation and basal endothelial NO synthesis (measured using an invasive method), and support the notion that endothelial dysfunction is a critical intermediate phenotype in the relationship between inflammation and cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10781383

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  55 in total

1.  C reactive protein and microvascular function.

Authors:  F Tomai
Journal:  Heart       Date:  2004-07       Impact factor: 5.994

2.  Elevations in C-reactive protein and endothelin-1 system activity in humans.

Authors:  Caitlin A Dow; Danielle L Templeton; Grace M Lincenberg; Jared J Greiner; Brian L Stauffer; Christopher A DeSouza
Journal:  Life Sci       Date:  2015-12-11       Impact factor: 5.037

3.  Early detection of C-reactive protein and von Willebrand factor levels in Malaysian patients with acute coronary syndrome.

Authors:  Wen Ni Tiong; Edmund Ui Hang Sim; Alan Yean Yip Fong; Tiong Kiam Ong
Journal:  J Cardiovasc Dis Res       Date:  2013-02-27

4.  The endothelial dysfunction in patients with type 2 diabetes mellitus is associated with IL-6 gene promoter polymorphism in Chinese population.

Authors:  Xianfeng Zhang; Lizhen Ma; Fengying Peng; Yin Wu; Yu Chen; Linying Yu; Zhikai Lei; Chu Zhang
Journal:  Endocrine       Date:  2011-03-18       Impact factor: 3.633

Review 5.  Obesity and coronary microvascular disease - implications for adipose tissue-mediated remote inflammatory response.

Authors:  Zsolt Bagi; Zuzana Broskova; Attila Feher
Journal:  Curr Vasc Pharmacol       Date:  2014-05       Impact factor: 2.719

6.  Thoracic fat volume is independently associated with coronary vasomotion.

Authors:  Vincent Dunet; François Feihl; Amin Dabiri; Gilles Allenbach; Bernard Waeber; Raphaël Heinzer; John O Prior
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-19       Impact factor: 9.236

Review 7.  Role of C-reactive protein in contributing to increased cardiovascular risk in metabolic syndrome.

Authors:  Sridevi Devaraj; Simona Valleggi; David Siegel; Ishwarlal Jialal
Journal:  Curr Atheroscler Rep       Date:  2010-03       Impact factor: 5.113

Review 8.  Adipocytokines in atherothrombosis: focus on platelets and vascular smooth muscle cells.

Authors:  Giovanni Anfossi; Isabella Russo; Gabriella Doronzo; Alice Pomero; Mariella Trovati
Journal:  Mediators Inflamm       Date:  2010-06-28       Impact factor: 4.711

Review 9.  The vasa vasorum in diseased and nondiseased arteries.

Authors:  Mary Jo Mulligan-Kehoe
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-11-25       Impact factor: 4.733

10.  Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT).

Authors:  Steven E Kahn; Steven M Haffner; Giancarlo Viberti; William H Herman; John M Lachin; Barbara G Kravitz; Dahong Yu; Gitanjali Paul; Rury R Holman; Bernard Zinman
Journal:  Diabetes Care       Date:  2009-10-06       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.